Kodiak Sciences Inc.

Kodiak Sciences develops advanced biologics for retinal vascular diseases. Its lead KSI‑301 is in Phase 3 trials for wet AMD, diabetic retinopathy, and retinal vein occlusion, targeting a high‑prevalence, growing US and global market.

Headquarters: United States (USA)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Professional Services
Industry: Biotechnology Research

Employees: 123
HQ: Palo Alto

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
KOD	Kodiak Sciences Inc. Cap: 1.7B	EQUITY	NGM	USD	US50015M1099	Active	📈